Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Myelodysplastic Syndromes (MDS)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    199 result(s) found for: Myelodysplastic Syndromes (MDS). Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-002935-23 Sponsor Protocol Number: GIMEMA MDS 0104 Start Date*: 2004-11-24
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO
    Full Title: Phase II study of PS341 VELCADE in myelodysplastic syndromes MDS.
    Medical condition: Patients with MDS
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028533 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001774-27 Sponsor Protocol Number: AISSM03 Start Date*: 2005-05-23
    Sponsor Name:AISSM ONLUS
    Full Title: CAMPATH-1H AS IMMUNOSUPPRESSIVE AGENT IN MDS PATIENTS MULTICENTRIC PILOT STUDY
    Medical condition: In this study we want to assess the potential of CAMPATH-1H as an immunosuppressive agent in a series of selected MDS patients, because T lymphocytes are thought to play an important role in the ...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028536 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001516-24 Sponsor Protocol Number: 20060197 Start Date*: 2007-08-23
    Sponsor Name:Amgen Inc
    Full Title: An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS)
    Medical condition: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) SE (Prohibited by CA) BE (Completed) DE (Completed) ES (Completed) HU (Completed) PL (Completed) CZ (Completed) AT (Completed) SK (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003986-20 Sponsor Protocol Number: LUCAS Start Date*: 2021-09-06
    Sponsor Name:Leipzig University
    Full Title: A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)
    Medical condition: Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004328-12 Sponsor Protocol Number: Europe Start Date*: 2015-01-23
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trial
    Medical condition: Patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-001321-28 Sponsor Protocol Number: AISSM02A Start Date*: 2005-06-13
    Sponsor Name:AISSM ONLUS
    Full Title: Phase II multicenter study of association of arsenic trioxide (ATO) and ascorbic acid in myelodisplastic syndromes
    Medical condition: Myelodisplastyc Syndrome treatment
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028536 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014768-21 Sponsor Protocol Number: TUD-TEMDS1-042 Start Date*: Information not available in EudraCT
    Sponsor Name:Dresden Technical University
    Full Title: Treatment of MDS patients with single agent temsirolimus – a pilot study
    Medical condition: Myelodysplastic Syndromes (MDS) (20 IPSS LOW+INT-1 and 20 IPSS INT-2+HIGH or proliferating CMML)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000727-13 Sponsor Protocol Number: 20130113 Start Date*: 2013-12-10
    Sponsor Name:Amgen Inc
    Full Title: Single arm, Companion Study to Myelodysplastic Syndrome (MDS) 20090160 Using Darbepoetin alfa for the Treatment of Anaemic Subjects With Myelodysplastic Syndrome
    Medical condition: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000812-41 Sponsor Protocol Number: GFM-EPO-PRETAR Start Date*: 2017-12-29
    Sponsor Name:GFM-Groupe Francophone des Myélodysplasies
    Full Title: A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WITHOUT DEL 5Q
    Medical condition: Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with transfusions independent anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000246-62 Sponsor Protocol Number: CICL670AAU01 Start Date*: 2016-03-07
    Sponsor Name:Novartis
    Full Title: A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferas...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022235-10 Sponsor Protocol Number: ITCC-015/EWOG-MDS-Azacytidine-2010 Start Date*: 2012-03-07
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMML
    Medical condition: Relapsed advanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10054439 Juvenile chronic myelomonocytic leukemia LLT
    20.0 100000004864 10068361 MDS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) IT (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003971-11 Sponsor Protocol Number: CICL670ADE03 Start Date*: 2007-04-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion...
    Medical condition: myelodysplastic syndrome and transfusion-dependent iron overload
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020341-27 Sponsor Protocol Number: GFM-Aza intensif Start Date*: 2010-06-22
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients
    Medical condition: Myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007258-75 Sponsor Protocol Number: 20060198 Start Date*: 2008-08-22
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndr...
    Medical condition: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS). ------------------------------------------------------------------------------ Síndrome Mielodisplásico (SMD) de Riesgo Bajo o Intermedio-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Prematurely Ended) NL (Completed) CZ (Prematurely Ended) IE (Completed) AT (Prematurely Ended) DE (Completed) HU (Completed) BE (Completed) GB (Completed) DK (Completed) SE (Prematurely Ended) FR (Completed) IT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004452-20 Sponsor Protocol Number: KCH-BMT-06-1.0 Start Date*: 2007-03-01
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Pilot study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients with Poor Risk Myelodysplastic Syndrome and Acute Myeloid Leukaemia utilising conditioning with Fludarabine, Bu...
    Medical condition: Myelodysplastic Syndrome Acute myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019673-15 Sponsor Protocol Number: BMT-AZA Start Date*: 2010-07-15
    Sponsor Name:Universit� Cattolica del Sacro Cuore
    Full Title: A open label, phase 2, non randomized, multicentre trial to assess the feasibility of induction treatment with 5-azacitidine (5-AZA) followed by allogeneic stem cell transplantation (allo-SCT) or ...
    Medical condition: myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002212-26 Sponsor Protocol Number: MK-0683-065 Start Date*: 2007-09-19
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes
    Medical condition: Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS)as defined by the International Prognostic Scoring System (IPSS).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003810-38 Sponsor Protocol Number: KCP-8602-801 Start Date*: 2021-12-01
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/R...
    Medical condition: High-risk primary refractory MDS patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028535 Myelodysplastic syndrome unclassifiable PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028534 Myelodysplastic syndrome NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067096 5q minus myelodysplastic syndrome LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067387 Myelodysplastic syndrome transformation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-008262-12 Sponsor Protocol Number: GFM-Len-Epo-08 Start Date*: 2009-10-05
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid®) with or without Epoetin beta (NeoRecormon®) in transfusion-dependent ESA-resistant patients with IPSS low- and interm...
    Medical condition: patients with IPSS low- and intermediate-1 risk myelodysplastic syndromes without chromosome 5 abnormality
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019709-41 Sponsor Protocol Number: GFM-Aza-ceplene Start Date*: 2010-10-13
    Sponsor Name:Groupe Francophone des Myélodysplasies
    Full Title: A phase I study of azacitidine with Ceplene/interleukin-2 followed by a randomized phase II study of the efficacy and safety of maintenance treatment with azacitidine with or without Ceplene/interl...
    Medical condition: Myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:38:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA